Pharmaceutical Business review

Merck announces FDA approval for hormone injection device

The device was designed to help patients administer a subcutaneous daily injection reliably and in just three steps.

A key feature of easypod is preset dosing, which means that patients no longer have to set their dose every day. It also tracks the number of doses administered, allowing physicians to monitor patient adherence to therapy.

Fereydoun Firouz, CEO and president of EMD Serono, said: “In today’s high-technology world, it is necessary to continue to innovate by developing delivery systems with easy-to-use settings and real-time data that empower patients and healthcare professionals to help improve patient care. easypod is an example of our commitment to breakthrough thinking and technology designed to answer unmet patient and caregiver needs.”